565 results about "Sulfonilamide" patented technology

The invention relates to the technical field of biological medicines, in particular to a sulfonamide compound for treatment and an enantiomer thereof as well as a preparation method and application thereof, and has the beneficial effects that the provided sulfonamide compound and the enantiomer thereof have the characteristics of strong stability, longer action effect, better drug effect and the like; the compound is a better diuretic and new anti-encephaledema medicine.

The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention relates to a substituted sulfonamide compound which is represented by formula (I) or a pharmacologically acceptable salt thereof. A compound according to the present invention, or a pharmacologically acceptable salt thereof, has an agonist activity against OX2R, and is useful as, for example, a therapeutic agent for sleep disorders associated with OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorders, insufficient sleep syndrome, and extended sleep).

The invention discloses a compound with a heteroaromatic ring sulfonamide structure as well as a pharmaceutical composition and application thereof. The invention provides a compound with a heteroaromatic ring sulfonamide structure as shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, tautomers or isotope compounds thereof. The compound with the heteroaromatic ring sulfonamide structure is expected to be used for treating and / or preventing various diseases related to poly adenosine diphosphate ribose hydrolase (PARG). # imgabs0 #

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of tow ore more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

Disclosed is a phenol-free, heat-sensitive recording material that comprises: (a) a substrate; and in order from a side close to the substrate, (b) an undercoat layer; and (c) a thermal-sensitive layer; wherein the thermal-sensitive layer comprises: a first developer comprising a sulfonamide compound represented by formula (1) below: wherein R1 and R2 may be the same or different, and each independently represents a hydrogen atom, an alkyl group having from 1 to 4 carbons, an alkoxy group having from 1 to 4 carbons, or a halogen atom, one or more second developers comprising at least one phenyl ureide compound represented by formula (2) below: wherein R3 and R4 may be the same or different, and each independently represents a hydrogen atom, a halogen atom, a nitro group, an amino group, an alkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylcarbonyloxy group, an arylcarbonyloxy group, an alkylcarbonylamino group, an arylcarbonylamino group, an alkylsulfonylamino group, an arylsulfonylamino group, a toluenesulfonyl group, a toluenesulfonyloxyphenyl group, a monoalkylamino group, a dialkylamino group, or an arylamino group, and one or more stabilizers selected from the group consisting of compounds represented by formula (3) and (4) below, and a derivative thereof.

The present invention relates to sulfonamides of Formula (I) which are inhibitors of PARG and are useful in the treatment of cancer.

The invention provides application of an aromatic sulfonamide compound in preparation of a medicine for preventing and treating liver injury. The aromatic sulfonamide compound BC2059 provided by the invention can be used for inhibiting transcription and protein synthesis of related genes of Fibronectin and CollagenI in hepatic stellate cells, and plays a role in treating liver injury mice induced by bile duct ligation and carbon tetrachloride. The invention provides a potential drug molecule with a new action mechanism for treating liver injury.

The invention belongs to the technical field of sulfonamide synthesis, and particularly relates to a green and environment-friendly sulfonamide amidation preparation method. Comprising the following steps: adding chlorosulfonic acid into a reactor, stirring, heating, adding o-nitrochlorobenzene, carrying out staged heat preservation, cooling, and adding thionyl chloride to obtain 2-nitro-4-chlorine sulfonate-chlorobenzene; the method comprises the following steps: separating and filtering 2-nitro-4-chlorine sulfonate-chlorobenzene, adding ammonia water, stirring, preserving heat, and carrying out filter pressing to obtain 2-nitro-4-amine sulfonate-chlorobenzene; the preparation method comprises the following steps: adding liquid caustic soda into 2-nitro-4-amine sulfonate-chlorobenzene, stirring, heating, and adjusting the pH value to obtain 2-nitro-4-amine sulfonate-phenol; the method comprises the following steps: adding water, a catalyst and hydrazine hydrate into 2-nitro-4-amine sulfonate-phenol, heating, stirring, and carrying out filter pressing to obtain 4-sulfonamide-2-amino-phenol. According to the preparation method of sulfonamide, generated tail gas is subjected to falling film absorption treatment, and the product prepared by the preparation method is high in purity.

The invention relates to the technical field of lithium metal battery polymer electrolyte, and discloses an amino lithium salt, a polymer electrolyte and a preparation method thereof. The structural formula of the lithium amide salt is as shown in formula (I) # imgabs0 #, R1 and R2 are independently selected from one of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and substituted or unsubstituted heteroatom-containing groups, and the lithium amide salt is prepared by reacting sulfonamide hydrochloride and sulfonyl chloride. The amino lithium salt and the single-ion conductor solid polymer electrolyte have the unique advantages that the lithium ion transference number is close to 1, the ion concentration gradient in the battery can be effectively reduced when the amino lithium salt and the single-ion conductor solid polymer electrolyte are used as the electrolyte, and the lithium ion transference efficiency is improved; and the method has important significance for improving the power density and the energy density of the lithium ion battery.

The invention discloses a preparation method of alplsutentan and an alplsutentan intermediate, alplsutentan is obtained by taking a compound SM1 as a raw material through a one-step method or a multi-step method, and the multi-step method comprises the following steps: reacting the compound SM1 with a compound SM2 to obtain an intermediate I; reacting the intermediate I with 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to obtain an intermediate II, or reacting the intermediate I with ethylene glycol to obtain an intermediate I-b, and then reacting with 5-bromo-2-chloropyrimidine or 5-fluoro-2-chloropyrimidine to obtain the intermediate II; and finally, removing a protecting group from the intermediate II to obtain alpoxivan. The one-step method comprises the following steps: when X in a compound SM1 is a fluorine atom, the compound SM1 is 5-(4-bromophenyl)-4, 6-difluoropyrimidine, and the compound SM1 reacts with sulfonamide and 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to directly obtain alpoxivan. The synthesis route is short, and the reaction conditions are mild.

A sulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, a preparation method for same and a use of same, and a pharmaceutical composition comprising same. The compound serves as a WDR5 inhibitor, has a remarkable effect as a WDR5 and Myc interaction blocker, and is beneficial to cancer treatment. A1 and A2 each are of a ring structure, and R1 and R2 are substituents.

The invention discloses a side group functionalized fluorine-containing polymer, a preparation method of the fluorine-containing polymer, an ion exchange membrane and application. The fluorine-containing polymer is obtained through the reaction of the functionalized reagent and the sulfonamide resin which is easily dispersed in the solvent, the reaction yield is increased, the main chain of the fluorine-containing polymer is of a perfluoro structure, the end group of the side chain is phenyl containing a substituent group, and the chemical stability of the end group is improved through a substituent group with high steric hindrance or a substituent group with high electronegativity; the sulfonyl imide functional group of the ion exchange membrane prepared from the fluorine-containing polymer has relatively strong gas-phase acidity, and the ion transmission capability of the material at high temperature is improved, so that the proton conductivity of the ion exchange membrane is improved, and the fluorine-containing polymer is suitable for a fuel cell ion exchange membrane, an ion exchange membrane for water electrolysis and a flow battery diaphragm.

The invention relates to a salt form of a pyrrole sulfonamide acid inhibitor as well as a preparation method and application of the salt form. Specifically, the invention discloses a compound shown as a formula (I), n = 0.1-2.0, and HA is an organic acid or an inorganic acid. The compound has the characteristics of convenience in storage, long-term stability of the product and simple preparation method, meets the industrial production requirements, and meets the development requirements of clinical pharmaceutical preparations. The compound disclosed by the invention can be used for preparing a potassium ion competitive acid blocker and preparing a medicine for treating gastric acid related diseases. # imgabs0 #

Provided in the present application is a compound represented by formula (I), or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer, a geometric isomer, a nitrogen oxide, a metabolite or a pharmaceutically acceptable salt, an ester, a solvate, a hydrate, an isotope-labeled compound or a prodrug thereof. The compound represented by formula (I) of the present application has a relatively ideal inhibitory activity with regard to KAT6A and / or KAT6B.

The invention relates to a crystal of a compound as shown in a formula I and a preparation method and application thereof. Specifically, the invention discloses a crystal of a compound shown as a formula I. The crystal form of the crystal is selected from the following groups: crystal form FormA, crystal form FormB, crystal form FormC or crystal form FormD, and n is equal to 0.1-2.0. The crystal form is good in stability, fluidity and moisture absorption resistance, and the preparation method of the crystal form is simple in process, easy to control and suitable for large-scale production. # imgabs0 #

The invention relates to an application of a sulfonamide compound or a pharmaceutical composition containing the sulfonamide compound in preparation of an anti-encephaledema drug. The sulfonamide compound can quickly reduce intracranial pressure, is used for treating encephaledema caused by various reasons and preventing cerebral hernia, is high in safety, has no serious adverse effects such as liver and kidney injury and the like, and is a novel anti-encephaledema medicine.

The invention discloses a polyamide composite material as well as a preparation method and application thereof. The polyamide composite material comprises the following components in parts by weight: 28-75 parts of polyamide resin; 3-10 parts of a gas phase reinforcing agent; 8-22 parts of an organic phosphorus flame retardant; 3-12 parts of a synergistic flame retardant; 8 to 32 parts of reinforcing fiber; wherein the gas phase enhancer comprises a compound containing a sulfonamide group, and melem and / or melam, and the mass ratio of the compound containing the sulfonamide group to the melem and / or melam is (0.5-3): 1. According to the invention, the compound containing the sulfonamide group and the melem and / or the melam in a specific mass ratio are added into the polyamide resin to serve as the gas phase enhancer, so that the glowing filament performance of the composite material can be improved, the mechanical property is better, and the mold scale is less.

To provide a resist material which has high sensitivity and improved LWR and CDU regardless of whether it is positive or negative, and a pattern forming method using the same.SOLUTION: The resist material contains a bis-onium salt containing: a divalent anion which has a sulfonic acid anion structure directly bonded to an aromatic group substituted with an iodine atom, and a sulfonimide anion structure or a sulfonamide anion structure bonded to the aromatic group directly or via a linking group containing one or more atoms; and an onium cation.SELECTED DRAWING: None

The invention discloses application of a sulfonamide ionic liquid catalyst system in preparation of cyclic carbonate, sulfonamide ionic liquid comprises cations and anions, and the cations are one or more of tetra-alkyl ammonium ions, tetra-alkyl phosphonium ions and trimethyl hydroxyethyl ammonium ions; the anion is one or more of sulfonamide ions or substituted sulfonamide ions; the sulfonamide ionic liquid is used as a catalyst and is used for catalyzing CO2 to react with an epoxy compound to prepare cyclic carbonate; the catalyst is easy to prepare and high in catalytic activity, under normal pressure, the dosage of the catalyst is 1-3 mol%, the reaction time is 1-48 hours, the reaction temperature is 25-100 DEG C, and a substituted epoxy compound can be converted into corresponding cyclic carbonate with high conversion rate and high selectivity. After the catalyst system is recycled for five times, the catalytic effect is not obviously reduced. Meanwhile, the catalyst system has good universality to substrates, and conversion of various epoxy compounds can be efficiently achieved.

The present invention addresses the problem of providing a novel compound that has OX2R agonist activity.　The present invention relates to a substituted sulfonamide macrocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof. This compound, or a pharmacologically acceptable salt thereof, has agonist activity against OX2R, and is useful as a treatment agent, etc., for sleep disorders involving OX2R (e.g., narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorder, insufficient sleep syndrome, and extended sleep).

The invention discloses a method for preparing 4-methoxycarbonyl-2-methylthiophene-3-sulfonamide, comprising the following steps: 1. preparing a sodium disulfide solution for standby; 2. reacting 4-amino-5-methylthiophene-3-methyl formate with sodium nitrite to obtain a diazo solution for standby; 3. reacting sodium disulfide with the diazo solution prepared in step 2 to obtain 3,3'-disulfide-bis[4-methoxycarbonyl-2-methylthiophene]; 4. reacting 3,3'-disulfide-bis[4-methoxycarbonyl-2-methylthiophene] with sulfonyl chloride; 5. adding water to separate layers, and treating the organic layer with ammonia to obtain 4-methoxycarbonyl-2-methylthiophene-3-sulfonamide. The invention provides a new preparation route for 4-methoxycarbonyl-2-methylthiophene-3-sulfonamide, wherein sulfur dioxide or chlorine is not used in the preparation process, thereby improving operational safety, reducing environmental pressure, reducing production costs, and being suitable for industrial production.

The use of a sulfonamide compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a stereoisomer thereof as a WDR5 inhibitor. The compound has a significant effect as a WDR5 and Myc interaction blocker, and is conducive to cancer treatment. A1 and A2 are ring structures, and R1 and R2 are substituents.

A precursor compound and a radioligand for cancer diagnosis and treatment comprises a high-affinity ligand PL for a cancer- associated protein conjugated to a covalent warhead CW for strong or covalent binding to an amino acid sidechain of the cancer-associated protein and a chelator Ch for complexation of a radioisotope or a leaving group LR for substitution with a radioisotope, wherein the covalent warhead CW is configured for quasi-covalent ionic binding using a sulfonic acid group or for covalent binding using a sulfur fluoride exchange (SuFEx) group, a benzotriazole or N-methyl-N- arylmethanesulfonamide leaving group or a malolactone group for strain-release alkylation.

Disclosed herein are compositions and methods for enhancing the ionic conductivity of a solid polymer electrolyte which comprise incorporating an additive that comprises at least one fluorinated sulfonamide compound selected from the group consisting of formulae (1) to (5) into the polymer matrix:and

The invention discloses an application of a benzenesulfonamide compound in preparation of a medicine for regulating sleep, and the structure of the benzenesulfonamide compound is as shown in the following formula: # imgabs0. The invention provides the application of the benzenesulfonamide compound in preparation of the medicine for regulating sleep for the first time. By intravenously injecting the benzenesulfonamide compound into the tail of the mouse, the sleep of the mouse can be promoted, the ratio of waking time of the mouse can be remarkably reduced, and the ratio of non-rapid eye movement sleep time and the ratio of rapid eye movement sleep time are increased.

This invention discloses an analytical method for benzothiazole contaminants, comprising the following steps: detection by high performance liquid chromatography (HPLC), with the following chromatographic conditions: a phenylhexyl column as the stationary phase, mobile phase A being water, mobile phase B being acetonitrile, and gradient elution; wherein the benzothiazole contaminants are at least one of 2-aminobenzothiazole, 2-hydroxybenzothiazole, benzothiazole, 2-methylbenzothiazole, 2-mercaptobenzothiazole, 2,5-dimethylbenzothiazole, 2-cyanobenzothiazole, ethyl 2-carboxylate benzothiazole, 2-chlorobenzothiazole, 2-bromobenzothiazole, 2-methylthiobenzothiazole, phenylthiocyanate, N-tert-butyl-2-benzothiazole sulfenamide, 2-(2-hydroxyphenyl)-benzothiazole, N-cyclohexyl-2-benzothiazole sulfinamide, dibenzothiazole disulfide, and N,N-dicyclohexyl-2-benzothiazole sulfonamide.

The lithium (N-carbonyl) sulfonamide compound is represented by the following formula (I). In formula (I), R 1 and R 2 Each represents an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkynyl group having 2 to 10 carbon atoms, or an aryl group. 1 and L 2 Each represents a single bond or -O-. Among them, excluding L 1 and L 2 Each is a single bond.

To provide a stable water treatment composition containing an inorganic sterilizing agent having high sterilization power and an azole compound, and a water treatment method using the water treatment composition.SOLUTION: The present invention provides a water treatment composition containing hypobromous acid, a bromine stabilizer, and an azole compound, and having a pH of 13 or more. The bromine stabilizer comprises (A) a sulfonamide compound and (B) a sulfobenzimide compound.SELECTED DRAWING: None